Arcutis Biotherapeutics, Inc.
$24.47
▼
-1.95%
2026-04-21 05:23:01
www.arcutis.com
NMS: ARQT
Explore Arcutis Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.04 B
Current Price
$24.47
52W High / Low
$31.77 / $12.42
Stock P/E
—
Book Value
$1.54
Dividend Yield
—
ROCE
-4.03%
ROE
-9.3%
Face Value
—
EPS
$-0.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
354
Beta
1.77
Debt / Equity
60.44
Current Ratio
3.17
Quick Ratio
2.99
Forward P/E
18.94
Price / Sales
7.98
Enterprise Value
$2.9 B
EV / EBITDA
-383.12
EV / Revenue
7.7
Rating
None
Target Price
$34.75
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 2. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
| 3. | NewcelX Ltd. | $2.83 | — | $12.13 M | — | 23.66% | 158.49% | $30.8 / $1.83 | $-11.28 |
| 4. | CEL-SCI Corporation | $3.94 | — | $33.32 M | — | -107.75% | -2.12% | $13.48 / $1.98 | $1.38 |
| 5. | iBio, Inc. | $1.97 | — | $70.3 M | — | -108.92% | -70.22% | $3.82 / $0.56 | $1.88 |
| 6. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 7. | Curanex Pharmaceuticals Inc | $0.48 | — | $12.79 M | — | -37.04% | -85.25% | $9.18 / $0.26 | $0.01 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 129.5 M | 99.22 M | 81.5 M | 65.85 M | 71.36 M | — |
| Operating Profit | 18.39 M | 8.53 M | -14.61 M | -24.53 M | -7.63 M | — |
| Net Profit | 17.39 M | 7.41 M | -15.89 M | -25.06 M | -10.79 M | — |
| EPS in Rs | 0.14 | 0.06 | -0.13 | -0.2 | -0.09 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 376.07 M | 196.54 M | 59.61 M | 3.69 M |
| Operating Profit | -12.23 M | -128.4 M | -241.1 M | -301.63 M |
| Net Profit | -16.14 M | -140.04 M | -262.14 M | -311.46 M |
| EPS in Rs | -0.13 | -1.13 | -2.11 | -2.51 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 432.97 M | 348.89 M | 341.37 M | 449.27 M |
| Total Liabilities | 243.49 M | 191.35 M | 252.7 M | 239.69 M |
| Equity | 189.48 M | 157.54 M | 88.67 M | 209.58 M |
| Current Assets | 411.23 M | 335.82 M | 330.43 M | 437.41 M |
| Current Liabilities | 129.84 M | 81.01 M | 46.67 M | 37.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -5.62 M | -112.16 M | -247.06 M | -257.71 M |
| Investing CF | -30.25 M | 28.82 M | 180.23 M | -87.2 M |
| Financing CF | 6.97 M | 66.2 M | 101.32 M | 301.8 M |
| Free CF | -16.31 M | -117.3 M | -247.49 M | -281 M |
| Capex | -10.69 M | -5.14 M | -0.43 M | -23.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 229.74% | 1517.09% | — | — |
| Earnings Growth % | 46.58% | 15.83% | — | — |
| Profit Margin % | -71.25% | -439.79% | -8449.76% | — |
| Operating Margin % | -65.33% | -404.49% | -8183.04% | — |
| Gross Margin % | 90.27% | 91.63% | 79.54% | — |
| EBITDA Margin % | -56.1% | -383.46% | -7999.78% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.